TICKERNERD
Menu
VTAKVTAKHealthcare · Medical Devices

VTAK Stock Forecast: Catheter Precision, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.21
−0.33% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$755,462.00
Ticker Nerd rank
27 / 100
Median analyst target
—
Analysts covering
1
Total return, dividends reinvested
1W
−25.3%
1M
−57.3%
YTD
−88.6%
1Y
−93.0%
From 52W high
−93.1%
From 52W low
0.0%
$0.21
$3.02
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VTAK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Catheter Precision, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
27 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Growth
87
Accruals
43
Issuance
38
Quality
35
Momentum
25
Revisions
25
Volatility
20
Value
5

Size (98): Smaller than most of the companies we track.

Value (5): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VTAK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VTAK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$0.50$1.00$1.50$2.00$2.50$3.00$3.50Oct 25Jan 26Apr 26Jul 26VTAK

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first

Of the 14 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
21 Oct 2021HC Wainwright & Co.InitiatesBuy$12
17 Mar 2021Maxim GroupDowngradeHold—
25 Nov 2020Cantor FitzgeraldMaintainsNeutral—
25 Nov 2020Piper JaffrayDowngradeNeutral—
25 Nov 2020Piper SandlerMaintainsNeutral—
25 Nov 2020PiperJaffrayInitiatesOverweight—
25 Nov 2020SunTrust Robinson HumphreyInitiatesBuy—
14 May 2020Piper SandlerMaintainsNeutral$1.50 → $1.00
11 Mar 2020Cantor FitzgeraldMaintainsNeutral$2.00 → $1.50
13 Aug 2019Piper JaffrayDowngradeNeutral—
13 Aug 2019Piper SandlerDowngradeNeutral$9.00 → $1.50
22 Oct 2018Cantor FitzgeraldInitiatesOverweight—
22 Oct 2018PiperJaffrayInitiatesOverweight—
22 Oct 2018SunTrust Robinson HumphreyInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VTAK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

VTAK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Catheter Precision, Inc. (VTAK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 74% of US stocks

Price / sales
0.4×

Cheaper than 86% of US stocks

Price / book
0.0×

Cheaper than 92% of US stocks

EV / EBITDA
−1.4×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
380.7%

Higher than 98% of US stocks

Earnings growth (YoY)
202.1%

Higher than 90% of US stocks

Gross margin
90.3%

Higher than 96% of US stocks

Operating margin
−388.1%

Higher than 8% of US stocks

Net margin
92.3%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−111.4%

Higher than 12% of US stocks

Return on assets
−24.3%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

VTAK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
VTAKCatheter Precision, Inc.$755,462.00
27
PFSAProfusa, Inc.$3.3M
13
IVFINVO Fertility, Inc.$2.7M
31
GCTKGlucoTrack, Inc.$3.7M
10
BJDXBluejay Diagnostics, Inc.$4.1M
20
NUWENuwellis, Inc.$4.2M
17
FEEDENvue Medical, Inc.$4.3M
23

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Catheter Precision, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VTAK news & analysis

Flyte Surpasses 10,000 Consumer Accounts as WebApp Growth Accelerates

GlobeNewsWire · 20 Aug 2026positive

Flyte, a subsidiary of Catheter Precision, Inc. (VTAK), announced that more than 10,000 consumer accounts are now registered on its Flyte WebApp, marking a milestone for the company's technology-enabled private aviation platform. New account creation increased 170% during the first 17 days of August compared to the same period in July, and the first-party customer base now spans 174 airports across 19 states.

Why it matters — This milestone indicates accelerating adoption and growth of Flyte, a subsidiary of VTAK, which is relevant to watchers of the parent company.

Flyte Partners with FullPAC to Bring Regional Aviation to the $11.4 Billion U.S. Political Campaign Market

GlobeNewsWire · 18 Aug 2026neutral

Flyte announced a strategic partnership with FullPAC to position itself as a regional aviation solution for statewide political campaigns, expanding access to more than 5,000 candidates, SuperPACs, and political organizations in the $11.4 billion U.S. political campaign market.

Why it matters — VTAK watchers would likely find this item neutral because it concerns aviation and political campaigns, with no direct connection to Catheter Precision's medical-device business.

Flyte Achieves Record Revenues in July

GlobeNewsWire · 6 Aug 2026positive

Flyte, a subsidiary of Catheter Precision, Inc. (VTAK), reported record monthly revenue for July 2026, increasing approximately 102% sequentially from June to about $640,000. The company attributed the growth to its retail platform, strategic partnerships, and influencer marketing, calling it the strongest operating month in Flyte's history.

Why it matters — A VTAK watcher would care because record sequential revenue growth at its Flyte subsidiary indicates accelerating demand within a key part of the parent company's operations.

Flyte Partners with Volato AI to Become First Enterprise Customer, Accelerating Technology Strategy to Scale Regional Private Aviation

GlobeNewsWire · 4 Aug 2026positive

Catheter Precision, Inc., through its wholly owned subsidiary Flyte, announced that Flyte has become the first enterprise customer of Volato AI, an artificial intelligence platform designed for business aviation. The deployment is expected to enhance customer experience, improve operating efficiency, and increase workforce productivity across flight operations, supporting Flyte's scalable regional air mobility platform.

Why it matters — For VTAK watchers, this marks Flyte's adoption of enterprise AI as part of the company's stated strategy to strengthen its scalable regional private aviation platform and drive long-term operational growth.

Volato AI Launches with Flyte as First Enterprise Customer

Business Wire · 4 Aug 2026neutral

Volato Group launched Volato AI, an enterprise AI platform for business aviation, with Flyte — a company owned by Catheter Precision, Inc. (VTAK) — as its first enterprise customer.

Why it matters — This deployment positions a VTAK subsidiary as an early adopter of AI technology in regional air mobility, which may influence the parent company's strategic direction.

FAQ

Frequently asked questions about VTAK stock

Is VTAK stock a buy right now?

Of the 1 analysts covering Catheter Precision, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Catheter Precision, Inc. 27 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VTAK?

As at 22 Aug 2026, Catheter Precision, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the VTAK stock forecast for 2030?

No analyst covering Catheter Precision, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VTAK are extrapolating price history, which says nothing about the business.

How has VTAK stock performed over the past year?

Catheter Precision, Inc. returned -93.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Catheter Precision, Inc. do?

Catheter Precision, Inc. is a dynamic player in the medical technology sector, specializing in the development and commercialization of advanced catheters and related technologies.

What is the latest news on VTAK?

The most recent item we track (GlobeNewsWire, 20 Aug 2026): "Flyte Surpasses 10,000 Consumer Accounts as WebApp Growth Accelerates". Flyte, a subsidiary of Catheter Precision, Inc. (VTAK), announced that more than 10,000 consumer accounts are now registered on its Flyte WebApp, marking a milestone for the company's technology-enabled private aviation platform. New account creation increased 170% during the first 17 days of August compared to the same period in July, and the first-party customer base now spans 174 airports across 19 states.

Company

About Catheter Precision, Inc.

Catheter Precision, Inc. is a dynamic player in the medical technology sector, specializing in the development and commercialization of advanced catheters and related technologies. The company focuses on providing innovative solutions for electrophysiology, a branch of cardiology that examines and treats arrhythmias. Their products are designed to support physicians in diagnosing and treating heart rhythm disorders with precision and efficacy. Notable features of Catheter Precision’s offerings include cutting-edge technology that enhances the accuracy of cardiac interventions and improves patient outcomes. As part of the broader healthcare sector, the company contributes to advancing medical treatments and has a significant impact on the quality of care provided to patients with cardiac issues. By continually innovating and integrating state-of-the-art technologies, Catheter Precision plays a crucial role in the electrophysiology market, offering tools that empower healthcare professionals to deliver superior cardiac care.

CEO Mr. David A. Jenkins · 17 employees · United States · https://www.catheterprecision.com